Skip to content

Hemodynamic Parameters in People With Atherosclerotic Vascular Disease Referred to a Secondary Prevention and Cardiovascular Rehabilitation Program

Evolution of Hemodynamic Parameters in People With Atherosclerotic Vascular Disease Referred to a Secondary Prevention and Cardiovascular Rehabilitation (PREV) Program: a Prospective Cohort Study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06701032
Enrollment
80
Registered
2024-11-22
Start date
2024-11-25
Completion date
2026-09-01
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Atherosclerosis, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Peripheral Artery Disease (PAD)

Keywords

cardiovascular rehabilitation, supervised exercise therapy, secondary prevention, cardiovascular secondary prevention, cardiovascular rehabilitation program, hemodynamics of lower limbs, toe pressure measurement

Brief summary

The main purpose of this study is to evaluate the hemodynamic changes in the forefoot of patients with coronary, cerebrovascular or peripheral atherosclerotic disease referred a 12-week cardiovascular rehabilitation program (PREV program). Also, this study will describe the characteristics of patients admitted to the PREV program and their evolutions in terms of favorable, unfavorable outcomes and complications and up to one year after completion of the program.

Interventions

The cardiovascular rehabilitation program consists of a 12 weeks supervised exercises therapy (either in person or in tele-care)

Sponsors

Laval University
Lead SponsorOTHER
CISSS de Chaudière-Appalaches
CollaboratorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any individual aged 18 years and older who has been diagnosed with peripheral artery disease, coronary artery disease, angina, ischemic heart failure, transient ischemic attack or ischemic stroke (non-cardioembolic, non-hemorrhagic); * Have been admitted to the PREV program;

Exclusion criteria

* Being not able to give written informed consent;

Design outcomes

Primary

MeasureTime frameDescription
Change in toe pressure measurementChange from baseline to 12 weeksResults will be measured in mm Hg
Change in the toe-brachial indexChange from baseline to 12 weeks
Change in the ankle-brachial indexChange from baseline to 12 weeks

Secondary

MeasureTime frameDescription
Change in 6-minute walk test (6MWT)Change from Baseline to 12 weeksResults will be measured in meters
Short Form Health Survey 36 (SF-36)Change from baseline to 12 weeksChange in quality of life measured using the SF-36 questionnaire. The scores range from 0-100.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026